Two High-Yielding Mid-Cap Spin-Offs On Sale (OGN & VTRS)

As I suspect that many have limited exposure to small- and mid-cap stocks, we’ve updated our special report, Small Companies, Big Potential. Mid-Cap Value Stocks are Attractive Kovitz We also offer a ...

Carvana, Meta, Palantir, Viatris, Walgreens and more

Budrul Chukrut | SOPA Images | Lightrocket | Getty Images Check out the companies making the biggest moves midday: Carvana — Carvana shares shed more than 15%, with trading briefly halted at one point...

Should I invest in Viatris shares after the current dip?

Viatris Inc. (NASDAQ: VTRS) shares have weakened from $10.20 to $8.42 since September 12, 2022, and the current price stands at $8.74. The U.S. stock market remains under pressure, and going forward, ...

Should I sell Viatris shares after Q2 results failed to meet revenue expectations?

Viatris Inc. (NASDAQ: VTRS) reported its second-quarter results on Monday and lowered the revenue outlook for the 2022 fiscal year. Michael Goettler, CEO of Viatris, said that because of strong operat...

Stocks Are Under Pressure. Add This Accounting Entry to the Risks.

Text size ADT recently valued its intangible assets at more than 200% of its market capitalization. Joe Raedle/Getty Images Weakening demand, inflation, and higher interest rates aren’t the only risks...

Is Viatris a good buy opportunity after the current dip?

Viatris Inc. (NASDAQ: VTRS) shares have weakened more than 20% after the company reported fourth-quarter results this Monday. Fourth-quarter results and revenue outlook disappointed several banks and ...

Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its busi...

Viatris to Sell Biosimilars Business for $3 Billion. Shares Tumble.

Viatris will sell the biosimilars business of the former Mylan to the Indian drugmaker Biocon for as much as $3.3 billion. Dreamstime Text size Viatris , the company formed in 2020 through a merger of...

Viatris Stock Hammered After Earnings, Asset Sale| Investor’s Business Daily

Viatris stock tumbled Monday after reporting mixed fourth-quarter earnings and a $3.34 billion plan to sell its biosimilars portfolio to Biocon Biologics. X The Biocon deal includes products expected ...

5 Companies That Began 2022 With Upbeat News on Dividends

Royalty Pharma, Life Storage, and Viatris, among other companies, rang in 2022 by announcing dividend increases this week. Royalty Pharma (ticker: RPRX) declared a quarterly dividend of 19 cents a sha...